Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models

Simone C. Oostindie, MSc, Hilma J. Van Der Horst, MSc, Marije B. Overdijk, PhD, Kristin Strumane, PhD, Sandra Verploegen, PhD, Margaret A. Lindorfer, PhD, Erica M. Cook, B.A., Martine E.D. Chamuleau, MD, Tuna Mutis, PhD, Janine Schuurman, PhD, A. Kate Sasser, PhD, Ronald P. Taylor, PhD, Paul W. H. I. Parren, PhD, Frank J. Beurskens, PhD, Esther C. W. Breij, PhD

Blood (2018) 132 (Supplement 1): 4170.

https://doi.org/10.1182/blood-2018-99-114723

Published: 2018

Journal Articles

Complement Activation in a Murine Model of Sickle Cell Disease: Inhibition of Vaso-Occlusion By Blocking C5 Activation

Terry Robert Schaid, Jr., BA, Julia Nguyen, BS, Chunsheng Chen, PhD, Fuad Abdulla, DVM, Trevor Killeen, Hao Nguyen, Joseph Edmund, MBBS, Margaret A Lindorfer, PhD, Ronald P Taylor, PhD, Agustin P Dalmasso, MD, John D Belcher, PhD, Gregory M Vercellotti, MD

Blood (2016) 128 (22): 158.

https://doi.org/10.1182/blood.V128.22.158.158

Published: 2016

Journal Articles

Enhanced IgG Hexamerization Mediates Efficient C1q Docking and Complement-Dependent Cytotoxicity; Preclinical Proof Of Concept On Primary CLL and Burkitt Lymphoma

Frank J Beurskens, PhD, Rob N de Jong, PhD, Sandra Verploegen, PhD, Marleen Voorhorst, Kristin Strumane, PhD, Margaret A. Lindorfer, PhD, Ronald P. Taylor, PhD, Erica Ollmann Saphire, PhD, Dennis Burton, PhD, Janine Schuurman, PhD, Paul W.H.I. Parren, PhD

Blood (2013) 122 (21): 375.

https://doi.org/10.1182/blood.V122.21.375.375

Published: 2013

Journal Articles

Resistance to Complement Dependent Cytotoxicity in CLL Cells From Patients Treated with Ofatumumab

Nisar A. Baig, Ronald P. Taylor, PhD, Margaret A. Lindorfer, PhD, Amy K Church, Betsy R. LaPlant, Emily S. Pavey, Tait D. Shanafelt, MD, Timothy G. Call, MD, Neil Kay, MD, Grzegorz S. Nowakowski, MD, Clive S. Zent, MD

Blood (2011) 118 (21): 2836.

https://doi.org/10.1182/blood.V118.21.2836.2836

Published: 2011

Journal Articles

C3-Mediated Extravascular Hemolysis In Paroxysmal Nocturnal Hemoglobinuria: An In Vitro Model to Dissect Complement C3 Activation Comparing the Effects of Complement Inhibitors Eculizumab, 3E7 and TT30 on C3 Fragment Processing and Hemolysis of PNH Erythrocytes

Antonio M. Risitano, MD, PhD, Caterina Pascariello, Luigi Del Vecchio, MD, Christopher J Horvath, DVM, MS, DACVP, Masha Fridkis-Hareli, PhD, V. Michael Holers, MD, Margaret A Lindorfer, PhD, Ronald P Taylor, PhD

Blood (2010) 116 (21): 637.

https://doi.org/10.1182/blood.V116.21.637.637

Published: 2010

Journal Articles

Complement Activation and Cytotoxicity In CLL Cells Treated with Alemtuzumab and Ofatumumab: Evidence for Multiple Mechanisms of Resistance to Complement Dependent Cytotoxicity

Nisar A Baig, Amy K Church, Grzegorz S. Nowakowski, MD, Ronald P Taylor, PhD, Margaret A Lindorfer, PhD, Clive S. Zent, MD

Blood (2010) 116 (21): 3575.

https://doi.org/10.1182/blood.V116.21.3575.3575

Published: 2010

Journal Articles

CLL Cells From Subjects Treated with Rituximab and Alemtuzumab Can Lose Target Antigen and Develop Resistance to Mab-Mediated Complement Dependent Cytotoxicity

Ronald P Taylor, PhD, Clive S. Zent, MD, Paul V Beum, PhD, Margaret A Lindorfer, PhD, George Weiner, MD

Blood (2010) 116 (21): 3585.

https://doi.org/10.1182/blood.V116.21.3585.3585

Published: 2010

Journal Articles

Examination of the Relative Rates of Rituximab-Mediated Loss of CD20 From B Cells Via Trogocytosis Versus Internalization. Implications for Rituximab Therapy of CLL

Ronald P Taylor, PhD, Paul V Beum, PhD, Margaret A Lindorfer, PhD, Elizabeth M Peek

Blood (2010) 116 (21): 2404.

https://doi.org/10.1182/blood.V116.21.2404.2404

Published: 2010

Journal Articles

A Novel Approach to Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Both Hemolysis and C3 Deposition Are Blocked by a Monoclonal Antibody (mAb) Specific for the Alternative Pathway of Complement (APC) C3/C5 Convertase.

Ronald P Taylor, PhD, Margaret A Lindorfer, PhD, Andrew W Pawluczkowycz, MS, Charles J Parker, MD

Blood (2009) 114 (22): 157.

https://doi.org/10.1182/blood.V114.22.157.157

Published: 2009

Journal Articles

Complement (C) Activation Followed by Penetration of the Membrane Attack Complex (MAC) on B Cells Opsonized with CD20 Mabs Allows for Calcium Influx Which Induces Streamers. Generalization of Streaming to Include other Mabs and Target Cells.

Ronald P. Taylor, PhD, Paul V. Beum, PhD, P. Todd Stukenberg, PhD, Andrew W. Pawluczkowycz, MS, Margaret A. Lindorfer, PhD, Frank J. Beurskens, PhD, Paul W. H. I. Parren, PhD, Jan G. J. van de Winkel, PhD

Blood (2008) 112 (11): 1577.

https://doi.org/10.1182/blood.V112.11.1577.1577

Published: 2008

Journal Articles

Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX.

Ronald P. Taylor, PhD, Andrew W. Pawluczkowycz, MS, Margaret A. Lindorfer, PhD, Jan G. J. van de Winkel, PhD, Frank J. Beurskens, PhD, Paul W. H. I. Parren, PhD

Blood (2008) 112 (11): 1578.

https://doi.org/10.1182/blood.V112.11.1578.1578

Published: 2008

Journal Articles

Spinning Disk Confocal Fluorescent Microscopy (SDCFM) Analyses of Complement Activation Promoted by Anti-CD20 Monoclonal Antibodies (mAbs) Rituximab and Ofatumumab.

Ronald P. Taylor, PhD, Paul V. Beum, PhD, Andrew W. Pawluczkowycz, Ms, Margaret A. Lindorfer, PhD, Frank Beurskens, PhD, Jan van de Winkel, PhD, Paul Parren, PhD

Blood (2007) 110 (11): 2345.

https://doi.org/10.1182/blood.V110.11.2345.2345

Published: 2007

Journal Articles

Complement Activation and Complement-Mediated Killing of B Cells Promoted by Anti-CD20 Monoclonal Antibodies (mAb) Rituximab and Ofatumumab Are Rapid, and Ofatumumab Kills Cells More Rapidly and with Greater Efficacy.

Ronald P. Taylor, PhD, Andrew W. Pawluczkowycz, Ms, Paul V. Beum, PhD, Margaret A. Lindorfer, PhD, Frank Beurskens, PhD, Jan van de Winkel, PhD, Paul Parren, PhD

Blood (2007) 110 (11): 2352.

https://doi.org/10.1182/blood.V110.11.2352.2352

Published: 2007

Journal Articles

Hematin Promotes Complement Alternative Pathway-Mediated Deposition of C3 Activation Fragments on Human Erythrocytes: Potential Implications for the Pathogenesis of Anemia in Malaria.

Ronald P. Taylor, PhD, Andrew W. Pawluczkowycz, Ms, Margaret A. Lindorfer, PhD, John W. Waitumbi, PhD

Blood (2007) 110 (11): 839.

https://doi.org/10.1182/blood.V110.11.839.839

Published: 2007

Journal Articles

The Shaving Reaction Is Facilitated through Trogocytosis: Concerted Transfer of Both Rituximab (RTX) and the Membrane Dye PKH26 from B Lymphocytes to Macrophages Is Demonstrable by Flow Cytometry, Fluorescence Microscopy, and High Resolution Digital Imaging in a Flow Cytometric Environment.

David A. Mack, MD, Paul V. Beum, PhD, Margaret A. Lindorfer, PhD, Andrew W. Pawluczkowycz, MS, Ronald P. Taylor, PhD

Blood (2006) 108 (11): 2096.

https://doi.org/10.1182/blood.V108.11.2096.2096

Published: 2006

Journal Articles

Flow Cytometry and Immunohistochemistry Analyses Reveal That Rituximab/CD20 Complexes Are Removed (Shaved) from Mantle Cell Lymphoma Cells (Z138) Previously Infused Intravenously or Subcutaneously in a SCID Mouse Model, and the Shaving Reaction Can Be Blocked by IVIG.

Ronald P. Taylor, PhD, Yongli Li, BS, Margaret A. Lindorfer, PhD, John B. Coursar, MD, Michael E. Williams, MD

Blood (2006) 108 (11): 2105.

https://doi.org/10.1182/blood.V108.11.2105.2105

Published: 2006

Journal Articles

Pilot Study of Thrice-Weekly Low-Dose Rituximab (RTX) in Chronic Lymphocytic Leukemia (CLL): Decreased CD20 Loss Via “Shaving” and a Novel Strategy for Enhanced Therapeutic Targeting.

Michael E. Williams, MD, John J. Densmore, MD, PhD, Andrew W. Pawluczkowycz, MS, Paul V. Beum, PhD, Adam D. Kennedy, PhD, Margaret A. Lindorfer, PhD, Susan H. Hamil, RN, Gina R. Petroni, PhD, Jane C. Eggleton, RN, Ronald P. Taylor, PhD

Blood (2005) 106 (11): 2970.

https://doi.org/10.1182/blood.V106.11.2970.2970

Published: 2005

Journal Articles

The Shaving Reaction. Rituximab/CD20 Complexes Are Removed from Mantle Cell Lymphoma Cells (Z138) and Chronic Lymphocytic Leukemia (CLL) Cells by Monocyte/Macrophages: In Vitro Studies and a SCID Mouse Model.

Ronald P. Taylor, PhD, Paul V. Beum, PhD, Yongli Li, MD, Margaret A. Lindorfer, PhD, Michael E. Williams, MD

Blood (2005) 106 (11): 2968.

https://doi.org/10.1182/blood.V106.11.2968.2968

Published: 2005

NARROW

Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models

Complement Activation in a Murine Model of Sickle Cell Disease: Inhibition of Vaso-Occlusion By Blocking C5 Activation

Enhanced IgG Hexamerization Mediates Efficient C1q Docking and Complement-Dependent Cytotoxicity; Preclinical Proof Of Concept On Primary CLL and Burkitt Lymphoma

Resistance to Complement Dependent Cytotoxicity in CLL Cells From Patients Treated with Ofatumumab

C3-Mediated Extravascular Hemolysis In Paroxysmal Nocturnal Hemoglobinuria: An In Vitro Model to Dissect Complement C3 Activation Comparing the Effects of Complement Inhibitors Eculizumab, 3E7 and TT30 on C3 Fragment Processing and Hemolysis of PNH Erythrocytes

Complement Activation and Cytotoxicity In CLL Cells Treated with Alemtuzumab and Ofatumumab: Evidence for Multiple Mechanisms of Resistance to Complement Dependent Cytotoxicity

CLL Cells From Subjects Treated with Rituximab and Alemtuzumab Can Lose Target Antigen and Develop Resistance to Mab-Mediated Complement Dependent Cytotoxicity

Examination of the Relative Rates of Rituximab-Mediated Loss of CD20 From B Cells Via Trogocytosis Versus Internalization. Implications for Rituximab Therapy of CLL

A Novel Approach to Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Both Hemolysis and C3 Deposition Are Blocked by a Monoclonal Antibody (mAb) Specific for the Alternative Pathway of Complement (APC) C3/C5 Convertase.

Complement (C) Activation Followed by Penetration of the Membrane Attack Complex (MAC) on B Cells Opsonized with CD20 Mabs Allows for Calcium Influx Which Induces Streamers. Generalization of Streaming to Include other Mabs and Target Cells.

Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX.

Spinning Disk Confocal Fluorescent Microscopy (SDCFM) Analyses of Complement Activation Promoted by Anti-CD20 Monoclonal Antibodies (mAbs) Rituximab and Ofatumumab.

Complement Activation and Complement-Mediated Killing of B Cells Promoted by Anti-CD20 Monoclonal Antibodies (mAb) Rituximab and Ofatumumab Are Rapid, and Ofatumumab Kills Cells More Rapidly and with Greater Efficacy.

Hematin Promotes Complement Alternative Pathway-Mediated Deposition of C3 Activation Fragments on Human Erythrocytes: Potential Implications for the Pathogenesis of Anemia in Malaria.

The Shaving Reaction Is Facilitated through Trogocytosis: Concerted Transfer of Both Rituximab (RTX) and the Membrane Dye PKH26 from B Lymphocytes to Macrophages Is Demonstrable by Flow Cytometry, Fluorescence Microscopy, and High Resolution Digital Imaging in a Flow Cytometric Environment.

Flow Cytometry and Immunohistochemistry Analyses Reveal That Rituximab/CD20 Complexes Are Removed (Shaved) from Mantle Cell Lymphoma Cells (Z138) Previously Infused Intravenously or Subcutaneously in a SCID Mouse Model, and the Shaving Reaction Can Be Blocked by IVIG.

Pilot Study of Thrice-Weekly Low-Dose Rituximab (RTX) in Chronic Lymphocytic Leukemia (CLL): Decreased CD20 Loss Via “Shaving” and a Novel Strategy for Enhanced Therapeutic Targeting.

The Shaving Reaction. Rituximab/CD20 Complexes Are Removed from Mantle Cell Lymphoma Cells (Z138) and Chronic Lymphocytic Leukemia (CLL) Cells by Monocyte/Macrophages: In Vitro Studies and a SCID Mouse Model.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only